Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:CHIR99021
gptkb:valproic_acid |
| gptkbp:administeredBy |
gptkb:physician
|
| gptkbp:announced |
2017
|
| gptkbp:clinicalTrialPhase |
Phase 2
|
| gptkbp:compatibleWith |
FDA (as of 2024)
|
| gptkbp:developedBy |
gptkb:Frequency_Therapeutics
|
| gptkbp:hasCompany |
gptkb:Lexington,_Massachusetts,_USA
|
| https://www.w3.org/2000/01/rdf-schema#label |
FX-322
|
| gptkbp:intendedUse |
treatment of sensorineural hearing loss
|
| gptkbp:mechanismOfAction |
regeneration of cochlear hair cells
|
| gptkbp:routeOfAdministration |
intratympanic injection
|
| gptkbp:status |
investigational
|
| gptkbp:target |
acquired sensorineural hearing loss
age-related hearing loss |
| gptkbp:bfsParent |
gptkb:Frequency_Therapeutics
|
| gptkbp:bfsLayer |
4
|